Syncona’s Freeline mulls IPO after crossovers back gene therapy play

Rather than draw the second half of a planned $80 million round from founding investor Syncona, gene therapy developer Freeline has instead opted to raise $80 million from a syndicate that includes crossover firms, setting up the company for a possible IPO.

Building on $40 million Syncona Ltd. (LSE:SYNC) had invested in December, the series C round now includes contributions from Novo Holdings A/S, Eventide Asset Management, Wellington Management Co., Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund...